دانلود ترجمه مقاله تجزیه و تحلیل کمی در مورد مقرون به صرفه بودن پزشکی
ترجمه در قالب فایل Word و قابل ویرایش میباشد
سال انتشار:2013
تعداد صفحه ترجمه:8
تعداد صفحه فایل انگلیسی:6
موضوع انگلیسی :Quantitative medical cost-effectiveness analysis of
molecular-targeting cancer drugs in Japan
موضوع فارسی:دانلود ترجمه مقاله تجزیه و تحلیل کمی در مورد مقرون به صرفه بودن پزشکی
چکیده انگلیسی:Background: In Japan, both incidence and mortality rates of cancers have continuously increased and medical
costs are growing more rapidly than the overall economy of Japan. However, there is no consensus threshold for
cost-effectiveness in medical care, and few studies have investigated cost-effectiveness of medical care in Japan.
The present study was to determine the direct costs of molecular-targeting drugs that were recently approved
in Japan through simple and quantitative calculations. Thus, we calculated an incremental cost-effectiveness
ratio (ICER) and the cost per life-year gained (LYG) by using reported data from randomized clinical trials for
various cancers.
Methods: Between 2008 and 2011, we reviewed seven molecular-targeting drugs that were approved for
treatment of five cancers in Japan. These drugs included Bevacizumab, sorafenib, sunitinib, temsirolimus, Lapatinib,
and panitumumab. Direct cost, ICER, and LYG of the drugs were estimated from the randomized phase III clinical
trial data referred to in package leaflets. Effectiveness was defined as the prolongation of both median overall
survival (OS) and progression-free survival (PFS). Costs were calculated as those of molecular-targeting drugs.
Subsequently, ICER was based on 1-month increases in both OS and PFS periods and 1% increases in OS, and LYG
was determined.
Results: Direct costs ranged from ¥724,804 ($9,060) to ¥1,506,628 ($18,833). ICERs of the drugs ranged from
¥724,804 ($9,060) to ¥1,506,628 ($18,833) for a 1-month increase in OS. For each month of PFS, ICERs ranged from
¥372,243 ($4,653) to ¥7,399,877 ($92,498). The costs of Bevacizumab and sorafenib for treatment of HCC per 1%
increase in OS were ¥376,657 ($4,708) and ¥313,733 ($3,922), respectively. LYG ranged from ¥8,697,650 ($108,721) to
¥18,079,530 ($225,994).
Conclusions: Some molecular-targeting drugs are not cost-effective. Considering ethical and moral issues,
we should establish economic endpoints to approve new drugs in Japan.
Keywords: Cost-effectiveness analysis, Molecular-targeting drugs, Simple quantitative calculation, Japan
چکیده فارسی:
چکیده :
سابقه و پس زمینه : در ژاپن ,هم شیوع بیماری و هم مرگ و میر ناشی از سرطان به طور مداوم افزایش یافته است و هزینه های پزشکی به سرعت بیش از کل اقتصاد ژاپن در حال افزایش است . با این حال, هیچ آستانه توافق برای مقرون به صرفه بودن مراقبت های پزشکی, در ژاپن وجود ندارد , این مطالعه , بر مقرون به صرفه بودن مراقبت های پزشکی در ژاپن متمرکز است . مطالعه حاضر به منظور تعیین هزینه های مستقیم اساس ملکولی داروهای سرطان, که اخیرا در ژاپن از طریق محاسبات ساده و کمی به تصویب رسیده است , انجام شده است . بنابراین, ما نسبت افزایشی مقرون به صرفه بودن (ICER) و هزینه هرسال زندگی (LYG) را با استفاده از اطلاعات گزارش شده از مطالعات کارآزمایی بالینی تصادفی در سرطان های مختلف, محاسبه میکنیم
